Partial
Needs Revision
Patient Risk:
Moderate
Summary
Partially aligned: several claims about indicated uses for recurrent genital herpes and labeled long-term suppressive re-evaluation are supported, but multiple statements introduce unlabeled indications (herpes labialis), non-labeled clinical practice generalizations, and specific monitoring/patient-contact triggers that are not present in the provided FDA label excerpts.
Category Scores
Accurate Statements
Long-term acyclovir is used for recurrent genital herpes.
Supported by INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION (Chronic Suppressive Therapy for Recurrent Disease).
Long-term acyclovir is used to reduce the frequency of outbreaks in people with frequent recurrences.
Supported by CLINICAL PHARMACOLOGY (Clinical Trials - Recurrent Genital Herpes) describing daily use preventing/reducing frequency and/or severity.
Long-term daily (suppressive) acyclovir is meant to prevent outbreaks from starting.
Supported by CLINICAL PHARMACOLOGY (daily for 4 months to 10 years prevents or reduces frequency/severity of recurrences) and DOSAGE AND ADMINISTRATION (re-evaluation for continuation).
Common side effects of long-term acyclovir can include nausea.
Supported by ADVERSE REACTIONS (Long-Term Administration: continuous 400 mg BID for 1 year—nausea 4.8%).
Common side effects of long-term acyclovir can include diarrhea.
Supported by ADVERSE REACTIONS (Long-Term Administration: continuous administration—diarrhea 2.4%).
Acyclovir is cleared through the kidneys.
Supported indirectly by CLINICAL PHARMACOLOGY (half-life/clearance dependent on renal function; dosage adjustment for reduced renal function).
Dosing is typically adjusted in patients with impaired renal function when taking acyclovir.
Supported by DOSAGE AND ADMINISTRATION (Patients With Acute or Chronic Renal Impairment) and CLINICAL PHARMACOLOGY (dosage adjustment recommended).
Some patients remain on suppressive acyclovir for years.
Supported by CLINICAL PHARMACOLOGY (treatment daily for 4 months to 10 years; 3-year study described).
A typical follow-up plan for someone on long-term acyclovir includes periodic reassessment of outbreak frequency.
Supported by DOSAGE AND ADMINISTRATION (After 1 year of therapy, re-evaluate frequency/severity to assess need for continuation).
Unsupported Statements
Long-term acyclovir is used for recurrent herpes labialis (cold sores).
Not supported by the provided INDICATIONS AND USAGE section (label indications provided are herpes zoster, genital herpes, and chickenpox).
Clinicians commonly use long-term acyclovir as chronic suppressive therapy.
Label describes chronic suppressive therapy regimens but does not support claims about how commonly clinicians use it.
Long-term daily (suppressive) acyclovir is not meant to cure an active episode once symptoms have begun.
Label states acyclovir is not a cure for genital herpes, but does not explicitly support the framed distinction about suppressive therapy not curing an active episode after symptoms begin.
When an outbreak is already occurring, patients usually switch to a shorter course of antiviral treatment.
Intermittent therapy for recurrences is described, but the label does not state patients 'usually switch' during active outbreaks.
Suppressive therapy is often considered when outbreaks are frequent or distressing.
Label supports frequent recurrences and suppressive therapy regimens, but does not state 'distressing' or that it is 'often considered.'
Common side effects of long-term acyclovir can include fatigue.
Fatigue is not listed in the provided ADVERSE REACTIONS for long-term administration.
Risk of kidney irritation or worsening kidney function with extended acyclovir is higher if the patient is dehydrated.
Label advises adequate hydration and cautions with renal impairment/nephrotoxic agents, but dehydration as an explicit risk factor is not stated in the provided excerpts.
Symptoms that should trigger medical contact with long-term acyclovir include reduced urination.
The provided label excerpts do not list reduced urination as a trigger for contacting a physician.
Symptoms that should trigger medical contact with long-term acyclovir include swelling.
Peripheral edema is listed as an observed adverse event, but the excerpts do not state 'swelling' as a patient-contact trigger.
Symptoms that should trigger medical contact with long-term acyclovir include sudden worsening of kidney-related lab results.
The provided label excerpts do not provide instructions to contact a physician for worsening kidney laboratory results.
Clinicians may monitor kidney function during extended acyclovir therapy.
The provided excerpts support dose modification and precautions in renal impairment, but do not explicitly state kidney function monitoring during extended therapy.
Resistance is uncommon in people with normal immune systems taking acyclovir.
The provided label excerpts do not discuss resistance frequency by immune status.
Resistance becomes more likely in people with weakened immune systems taking acyclovir.
The provided label excerpts do not discuss resistance risk by immune status.
Resistance is more likely in people with advanced HIV taking acyclovir.
The provided label excerpts do not address HIV-related resistance.
Resistance is more likely in transplant recipients taking acyclovir.
The provided label excerpts do not address transplant-related resistance.
Resistance is more likely in cancer patients receiving immunosuppressive therapy taking acyclovir.
The provided label excerpts do not address cancer/immunosuppression-related resistance.
In resistant cases, clinicians may switch to alternative antivirals.
The provided label excerpts do not discuss management of resistance with alternative antivirals.
A typical follow-up plan for someone on long-term acyclovir includes periodic reassessment of side effects.
The label advises re-evaluation after 1 year for frequency/severity; it does not explicitly describe 'periodic reassessment of side effects' as a follow-up plan.
A typical follow-up plan for someone on long-term acyclovir includes kidney function checks as clinically appropriate.
The excerpts support renal dose modification and emphasize hydration/cautions, but do not explicitly state kidney function checks as a follow-up plan for extended therapy.
Some patients may trial stopping suppressive acyclovir to see whether outbreaks still occur frequently.
The label requires re-evaluation after 1 year to assess need for continuation, but does not describe a specific 'trial stopping' strategy.
Acyclovir, valacyclovir, and famciclovir are antiviral options used for similar herpes indications.
The provided label excerpts do not mention valacyclovir or famciclovir or indicate cross-drug similar indication usage.
Acyclovir, valacyclovir, and famciclovir differ in dosing convenience and dosing schedules.
The provided label excerpts do not compare other antivirals’ dosing convenience/schedules.
Long-term suppression strategies often use whichever option fits the patient's regimen, kidney function, and tolerability.
The provided label excerpts discuss acyclovir regimen/renal precautions, but do not support a generalized strategy using different antivirals.
Contradictions
Important Omissions
The label includes specific guidance for chronic suppressive therapy dosing (e.g., 400 mg twice daily for up to 12 months, followed by re-evaluation) and notes alternative regimens; the extracted claims largely omit these labeled dosing details.
Importance:
Moderate
The label explicitly states: acyclovir is intended for oral ingestion only for oral suspension, and provides multiple specific renal impairment and dialysis dosing adjustments; extracted claims do not reflect these detailed administration modifications.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims introduce non-labeled patient guidance (e.g., specific symptoms like reduced urination/swelling/lab changes as contact triggers) and unlabeled indications (herpes labialis). While they do not directly state unsafe dosing, they could mislead labeling-accurate clinical and monitoring expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Low |
Recommendation
Needs Revision
Primary Issue
Multiple extracted claims are not supported by the provided FDA label excerpts, including an unlabeled indication (herpes labialis) and several non-label patient monitoring/management generalizations.
Suggested Improvement
Remove or rephrase unsupported items to match labeled indications (herpes zoster, genital herpes, chickenpox) and labeled chronic suppressive therapy guidance (dose regimen and re-evaluation after 1 year). Avoid adding specific patient-contact triggers (e.g., reduced urination, kidney labs worsening) or resistance-by-subpopulation statements unless present in the provided label sections.